Bevacizab 100mg Injection

About

Bevacizab 100mg Injection is a recombinant humanized monoclonal antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor (VEGF). VEGF is a key mediator of angiogenesis, a process critical for tumor growth and metastasis. By inhibiting VEGF, this injection reduces tumor vascularization, thereby limiting the supply of oxygen and nutrients to the tumor cells and inhibiting their proliferation. This mechanism makes it an effective agent in various solid tumors, including metastatic colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. Its targeted action helps to starve tumors of their blood supply, thereby slowing their progression and improving patient outcomes when used in combination with chemotherapy.

Uses

• Metastatic colorectal cancer
• Non-small cell lung cancer
• Metastatic renal cell carcinoma
• Recurrent glioblastoma

Directions For Use

Administered intravenously by a healthcare professional. Dosage and infusion rate are determined by the patient's condition and body weight.

Benefits

• Inhibits tumor angiogenesis
• Slows tumor growth and progression
• Improves progression-free survival
• Can be used in combination with chemotherapy
• Targets a specific pathway in cancer development
• Offers a treatment option for various advanced cancers

Side Effects

• Hypertension
• Proteinuria
• Thromboembolic events
• Hemorrhage
• Gastrointestinal perforation
• Wound healing complications
• Fatigue
• Headache
• Diarrhea
• Nausea
• Neutropenia
• Taste alteration

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake during cancer treatment.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm; use effective contraception during and for 6 months after treatment.
• Breastfeeding - Not recommended during breastfeeding due to potential for serious adverse reactions in the infant.
• Liver - Use with caution in patients with severe liver impairment; dose adjustments may be necessary.
• Kidney - Use with caution in patients with severe renal impairment; monitor for proteinuria and renal function.
• Lung - Monitor for pulmonary hemorrhage and other lung-related adverse events, especially in patients with lung cancer.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.